Associations of longitudinal plasma p-tau181 and NfL with tau-PET, Aβ-PET and cognition
Abstract
To explore if changes over time of plasma phosphorylated tau (p-tau)181 and neurofilament light chain (NfL) predict future tau and amyloid β (Aβ) PET load and cognitive performance, we studied a subsample of the Alzheimer’s disease (AD) neuroimaging cohort with longitudinal blood peptide assessments.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 29, 2021
- Source ID
- 10.1136/jnnp-2020-325537
Entities
People
- Boris-Stephan Rauchmann
- Robert Perneczky
- Thomas Schneider-axmann
Organizations
- AbbVie
- Alzheimer's Association
- Alzheimer's Drug Discovery Foundation
- BioClinica
- Biogen
- Bristol-Myers Squibb
- Canadian Institutes of Health Research
- Chiron Corporation
- Eisai (South Korea)
- Eli Lilly and Company
- GE HealthCare
- Hoffmann-La Roche
- IXICO
- Johnson & Johnson Pharmaceutical Research and Development
- Laboratoires Servier
- Lundbeck
- Merck & Co.
- Meso Scale Diagnostics (United States)
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Institutes of Health
- Pfizer
- Roche (United States)
- Takeda Pharmaceutical Company
- United States Department of Defense